Dyadic International signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. The Rubic Consortium is made up of promoters of the project representing public health, medical, academia, vaccine technology, technology transfer and economics sectors. Arrangement includes C1 COVID-19 vaccine technology transfer and licensing...
Biotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study: FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical...
On 4/20/2021 HC Wainwright brokerage Reiterated Rating to Buy and a Price Target of $16.00 for NRBO But how come? What`s the catalyst? Why NeuroBo Pharmaceuticals was up 40% yesterday? Richard J. Kang, CEO: "Throughout the first quarter of 2021, we continued to make progress advancing the 60-patient Phase 2/3 clinical trial of our lead drug candidate, ANA001,...
Since Covid-19 is here to stay with us with its variants and the vaccines don`t offer lifetime protection, this means that there is room for other companies to develop a better vaccine to address the problem. And the gains in vaccines stock are quite similar to cryptocurrencies year over year. From all time low to all time high, BNTX made 19X, MRNA 24X and NVAX...
On 6/15/2021 Cantor Fitzgerald brokerage Boosted the Price Target from Reduce to Overweight $217.00 to $272.00 On 5/18/2021 JPMorgan Chase & Co. brokerage Reiterated Rating from Overweight to Neutral $285.00 to $161.00 On 5/12/2021 B. Riley brokerage Lowered the Price Target from $365.00 to $286.00 On 5/12/2021 HC Wainwright brokerage Lowered the...
VXA-CoV2-1, Vaxart's experimental treatment for Covid-19 is unique in that it's a pill, not an injection. A pill would certainly be easier from a distribution and administration standpoint but also to get higher vaccination rates. On May 3, Vaxart's treatment showed demonstrable CD8 T-cell responses, but didn't produce high levels of neutralizing antibodies...
With the new Covid-19 Delta Variant which is more contagious than the other virus strains the question is if you want to get vaccinated or get COVID-19. PFE Pfizer has a great vaccine, a decent P/E Ratio (TTM) of 20.34, pays Forward Dividend & Yield of 1.56 (3.89%) and it is not at all time high like MRNA for example. Expected sales from vaccine in 2021:...
I absolutely hate this company. - Moving averages suggest bullish trend. - 3rd attempt at major resistance. - Doji Candle formed = change in trend/momentum. - "Inside Day" pattern formed = Suggesting a continuation of the current trend. In this situation, it should continue the uptrend for a short period of time until a new pattern/confluence forms. - However,...
Quick check in the COVID-19 situation for Singapore shows that there is some level of stabilization. As more cases and clusters surface, this may be the eye of the storm, and the next weeks will show us what might come in June... Watch for it!
If you haven`t longed Moderna with me from here: Then you should realize that the head an shoulders pattern on descending volume of a company that worth 53.402B, but has 747Mil negative earnings for 2020, may lead to $100 per share. On the other hand, undervalued, it`s Pfizer , which has the same amazing results with the vaccine, lots of medicine in the...
The British pound has recorded considerable losses on Wednesday and fallen below the 1.38 line. Currently, GDP/USD is trading at 1.3775, down 0.63% on the day. The UK released a mixed employment report earlier on Tuesday. In February, claims jumped to 86.6 thousand, compared to the forecast of 9.0 thousand. This was the highest claim count since July. The...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants Expanding existing COVID-19 vaccine research collaboration which began in July 2020. Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19...
on news - www.fiercebiotech.com 78 and 81 are first and second targets
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis. finance.yahoo.com
CVS has been on a downtrend for the past three weeks and finally has broken out. I'm looking at a PT of 81.
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating...
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg - Company secures next step to continue to build-out pipeline of assets. - University researchers developed a proprietary and orally active bacterial vaccine...
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19 announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific...